Studies have showed that S100A9 treatment enhanced the survival and invasiveness of three hepatoma cell lines, HepG2, SMMC-7721, and Huh7, and S100A9 also facilitated tumor development in vivo in a xenograft mouse model. This evidence concerns the gene S100A9 and hepatocellular carcinoma.